Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis
<p>Abstract</p> <p>Background</p> <p>Resistance to apoptosis is a major problem in ovarian cancer and correlates with poor prognosis. Osteoprotegerin (OPG) is a secreted factor in malignant ascites and acts as a decoy receptor for receptor activator of NF-κB ligand (RAN...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2012-11-01
|
| Series: | Journal of Ovarian Research |
| Subjects: | |
| Online Access: | http://www.ovarianresearch.com/content/5/1/34 |
| _version_ | 1797969079546413056 |
|---|---|
| author | Lane Denis Matte Isabelle Rancourt Claudine Piché Alain |
| author_facet | Lane Denis Matte Isabelle Rancourt Claudine Piché Alain |
| author_sort | Lane Denis |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Resistance to apoptosis is a major problem in ovarian cancer and correlates with poor prognosis. Osteoprotegerin (OPG) is a secreted factor in malignant ascites and acts as a decoy receptor for receptor activator of NF-κB ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). TRAIL promotes apoptosis in ovarian cancer cells. Ovarian cancer ascites attenuate TRAIL-induced apoptosis raising the possibility that OPG contained in ascites may abrogate the anti-tumor activity of TRAIL.</p> <p>Methods</p> <p>Determination of OPG levels in ascites was measured by ELISA. Effect of OPG on TRAIL-induced cell death was determined by XTT and colony forming assays in ovarian cancer cell lines and primary tumor cells. Apoptosis was assessed by ELISA.</p> <p>Results</p> <p>We found that recombinant OPG and malignant ascites attenuates TRAIL-induced cell death and apoptosis in a dose-dependent manner in ovarian cancer cell lines and primary ovarian tumor cells. OPG is present at high levels in the ascites of patients with ovarian cancer. We found a positive correlation between the levels of OPG in ascites and the ability of the ascites to attenuate TRAIL-induced cell death. The anti-apoptotic effect of ascites was not reversed by co-incubation with an OPG blocking antibody.</p> <p>Conclusions</p> <p>OPG and malignant ascites protect ovarian cancer cells from TRAIL-induced apoptosis. Although malignant ascites contain high levels of OPG, OPG is not a critical component that contributes to ascites-mediated attenuation of TRAIL-induced apoptosis.</p> |
| first_indexed | 2024-04-11T02:55:28Z |
| format | Article |
| id | doaj.art-99673aab534b486aa533dd1d7bf8764b |
| institution | Directory Open Access Journal |
| issn | 1757-2215 |
| language | English |
| last_indexed | 2024-04-11T02:55:28Z |
| publishDate | 2012-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Ovarian Research |
| spelling | doaj.art-99673aab534b486aa533dd1d7bf8764b2023-01-02T15:15:56ZengBMCJournal of Ovarian Research1757-22152012-11-01513410.1186/1757-2215-5-34Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosisLane DenisMatte IsabelleRancourt ClaudinePiché Alain<p>Abstract</p> <p>Background</p> <p>Resistance to apoptosis is a major problem in ovarian cancer and correlates with poor prognosis. Osteoprotegerin (OPG) is a secreted factor in malignant ascites and acts as a decoy receptor for receptor activator of NF-κB ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). TRAIL promotes apoptosis in ovarian cancer cells. Ovarian cancer ascites attenuate TRAIL-induced apoptosis raising the possibility that OPG contained in ascites may abrogate the anti-tumor activity of TRAIL.</p> <p>Methods</p> <p>Determination of OPG levels in ascites was measured by ELISA. Effect of OPG on TRAIL-induced cell death was determined by XTT and colony forming assays in ovarian cancer cell lines and primary tumor cells. Apoptosis was assessed by ELISA.</p> <p>Results</p> <p>We found that recombinant OPG and malignant ascites attenuates TRAIL-induced cell death and apoptosis in a dose-dependent manner in ovarian cancer cell lines and primary ovarian tumor cells. OPG is present at high levels in the ascites of patients with ovarian cancer. We found a positive correlation between the levels of OPG in ascites and the ability of the ascites to attenuate TRAIL-induced cell death. The anti-apoptotic effect of ascites was not reversed by co-incubation with an OPG blocking antibody.</p> <p>Conclusions</p> <p>OPG and malignant ascites protect ovarian cancer cells from TRAIL-induced apoptosis. Although malignant ascites contain high levels of OPG, OPG is not a critical component that contributes to ascites-mediated attenuation of TRAIL-induced apoptosis.</p>http://www.ovarianresearch.com/content/5/1/34OsteoprotegerinTRAILOvarian carcinomaResistanceAscitesApoptosis |
| spellingShingle | Lane Denis Matte Isabelle Rancourt Claudine Piché Alain Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis Journal of Ovarian Research Osteoprotegerin TRAIL Ovarian carcinoma Resistance Ascites Apoptosis |
| title | Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis |
| title_full | Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis |
| title_fullStr | Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis |
| title_full_unstemmed | Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis |
| title_short | Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis |
| title_sort | osteoprotegerin opg protects ovarian cancer cells from trail induced apoptosis but does not contribute to malignant ascites mediated attenuation of trail induced apoptosis |
| topic | Osteoprotegerin TRAIL Ovarian carcinoma Resistance Ascites Apoptosis |
| url | http://www.ovarianresearch.com/content/5/1/34 |
| work_keys_str_mv | AT lanedenis osteoprotegerinopgprotectsovariancancercellsfromtrailinducedapoptosisbutdoesnotcontributetomalignantascitesmediatedattenuationoftrailinducedapoptosis AT matteisabelle osteoprotegerinopgprotectsovariancancercellsfromtrailinducedapoptosisbutdoesnotcontributetomalignantascitesmediatedattenuationoftrailinducedapoptosis AT rancourtclaudine osteoprotegerinopgprotectsovariancancercellsfromtrailinducedapoptosisbutdoesnotcontributetomalignantascitesmediatedattenuationoftrailinducedapoptosis AT pichealain osteoprotegerinopgprotectsovariancancercellsfromtrailinducedapoptosisbutdoesnotcontributetomalignantascitesmediatedattenuationoftrailinducedapoptosis |